Matching articles for "Slynd"
Addendum: Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • March 23, 2020; (Issue 1594)
In our article on Slynd (Med Lett Drugs Ther 2020; 62:18),
the drospirenone-only oral contraceptive, we mentioned that
drospirenone has antiandrogenic activity that could improve
acne and...
In our article on Slynd (Med Lett Drugs Ther 2020; 62:18),
the drospirenone-only oral contraceptive, we mentioned that
drospirenone has antiandrogenic activity that could improve
acne and antimineralocorticoid activity that could cause
hyperkalemia. We should have added that concurrent use of
drospirenone with other drugs that increase potassium levels,
such as the anti-androgen aldosterone receptor antagonist
spironolactone (Aldactone, and generics), which is often
used off-label for treatment of acne, can increase the risk of
hyperkalemia.
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • February 10, 2020; (Issue 1591)
The FDA has approved a progestin-only oral
contraceptive ("minipill") containing drospirenone
(Slynd – Exeltis). All other progestin-only oral
contraceptives available in the US contain
norethindrone...
The FDA has approved a progestin-only oral
contraceptive ("minipill") containing drospirenone
(Slynd – Exeltis). All other progestin-only oral
contraceptives available in the US contain
norethindrone (Camila, and others). Progestin-only oral
contraceptives are similar in efficacy to combination
oral contraceptives. They are used predominantly by
breastfeeding women and by those in whom estrogen
is poorly tolerated or contraindicated. Combination
oral contraceptives containing drospirenone and
ethinyl estradiol have been available for years.